Vertex Pharmaceuticals is mentioned in a Loomis Sayles letter regarding Trump-era tariffs and onshoring trends.
1 report, 1 independent
Updated Sep 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Vertex Pharmaceuticals is mentioned in a Loomis Sayles letter regarding Trump-era tariffs and onshoring trends.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Vertex Pharmaceuticals
American pharmaceutical company
Related events
- The new event concerns the impact of Trump-era tariffs and onshoring trends on Viatris.
- Elastic benefits from the trend of onshoring and tariffs associated with the Trump administration.
- Global tariffs from Donald Trump began on August 4, 2025, impacting international markets and financial news services like Bloomberg L.P.
- Trump's tariff plan caused markets to tank, affecting company Flo.
- The Trump administration is currently negotiating tariffs.
Coverage
Newest first; wire copies grouped- Insider MonkeyHere’s Why Vertex Pharmaceuticals (VRTX) is on Loomis Sayles Growth Fund’s Detractors List Loomis Sayles, an investment management company, released its “Growth Fund” second-quarter 2025 investor let